Research overview
Over 50,000 people are diagnosed with a myeloid neoplasm every year in the U.S. alone. A high-risk subset of these patients is unresponsive to current treatments and their survival is less than a year, a rate that has remained unchanged for the last 40 years. The long-term goal of our work is to improve the outcome for these patients. To accomplish this, research in the lab focuses on understanding the underlying genomic abnormalities in high-risk myeloid neoplasms, to identify new treatment options.
Functional genomics
We use a variety of next-generation approaches to decipher the cancer genome.
NEWS
Congratulations to Matt Jotte and Kasia Zawieracz who received the Fitch Travel Award and Mary Ellen Connellan Scholarship for Cancer Biology, respectively
We’re delighted to have new graduate student, Yuqing Xue, join the team!
The lab extends a warm welcome to Dr. Joseph Cannova, who joins the team this month
Selected Metrics